Alexej Ballhausen

TL;DR: It is demonstrated that Lynch syndrome colorectal cancers can develop through three pathways, with MMR deficiency commonly representing an early and possibly initiating event, and underlines that targeting MMR‐deficient cells by chemoprevention or vaccines against MMR deficiency‐induced frameshift peptide neoantigens holds promise for tumor prevention in Lynch syndrome.

TL;DR: The results show that frameshift mutation frequency is negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting counterselection of cell clones with highly immunogenic frameshIFT peptides.

TL;DR: High HEV densities in B2M-mutant tumours underline the significance of immunoediting during tumour evolution and indicate a significant contribution of lymphocyte trafficking in immune responses against MSI CRC, particularly in the context of Lynch syndrome.

TL;DR: IMC-A12 was very well tolerated, however, showed limited clinical activity in uveal melanoma as a single agent due to its low toxicity profile, and could be studied in combination with other pathway-specific agents.

TL;DR: In this paper, the authors examined the prevalence of Beta-2-microglobulin (B2M) mutations, a common immune evasion mechanism, in stage IV MSI gastrointestinal cancer and its influence on metastatic pattern and patients' survival under ICB.